Navigation Links
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
Date:4/29/2013

dy author. "These patients are in many ways more fragile, and at greater risk from spinal surgery, than patients with other types of diseases or injuries where our cell therapy may be applicable. That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in the las
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
2. Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention
3. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
4. Neuralstem Secures $8 Million In Debt Financing From Hercules
5. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
6. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
7. Neuralstem to Raise $7.0 Million in Registered Direct Offering
8. Neuralstem Announces Proposed Public Offering
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
11. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... September 2, 2015 The ... global clinical trials review of H2, 2015 provides ... an objective to enhance decision making capabilities of ... report on Keratoconus market clinical trials review spread ... institutes / government organizations and supported with 43 ...
(Date:9/1/2015)... BRISBANE, Australia and Delaware , ... -- Invion Limited (ASX: IVX; "Company" or "Invion"), is pleased ... issue the following securities to an institutional investor in ... for aggregate gross proceeds of approximately A$1.001 million ("Placement") by ... an issue price of $0.014 per share. ...
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
Breaking Medicine Technology:Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3
... Complete,Genomics Inc., a newly launched, third-generation human ... (ISB) today announced their,partnership to conduct populationwide human ... project, Complete Genomics will use its proprietary,DNA sequencing ... by,ISB. Then, once proof-of-concept has been demonstrated, ISB ...
... 6 Dendreon Corporation (Nasdaq:,DNDN) will host a ... 9:00 AM,ET (6:00 AM PT) to review the ... for Prostate AdenoCarcinoma Treatment, also known as D9902B),clinical ... immunotherapy for the treatment of advanced prostate,cancer., ...
Cached Medicine Technology:Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker ... for HCPro and Associate Director of Education for the Association for Clinical Documentation Improvement ... ICD-10 for CDI Boot Camps. She serves as a CDI subject matter expert for ...
(Date:9/2/2015)... Appleton, WI (PRWEB) , ... September 02, 2015 ... ... Midwest, Cypress Benefit Administrators is taking action after seeing a significant ... The TPA’s Argus Claim Review division has found many cases of OON ASCs ...
(Date:9/2/2015)... ... 2015 , ... The 2015 China Overseas Investment and Entrepreneurship ... conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai State ... feature leading EB-5 industry professionals and Chinese private equity partners looking for international ...
(Date:9/2/2015)... ... 02, 2015 , ... Amada Senior Care, premier provider of in-home care and ... Johnson County location. Amada franchise partners Mike and Mell Fleming came to the ... spent over 20 years in medical device sales while Mell spent over 30 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... SonicSurg Innovations, ... market, announced today that more than 600 successful patient procedures have been performed ... Plus, nearly 70 of these procedures have been on triggering thumbs. , ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2
... in lab tests, researchers say , FRIDAY, Feb. 26 ... after diagnosis, but researchers have identified an oncogene that ... Even more hopeful is that drugs that target this ... are undergoing tests with colon and lung cancers, said ...
... for autism, stroke and other conditions , FRIDAY, ... of children,s brains during reading discovered something rather unexpected: ... of white matter tracts in the brain, and the ... out words. , "This is the first evidence ...
... account, researcher says , FRIDAY, Feb. 26 (HealthDay News) ... for pregnant women and their unborn babies mean that ... diagnosed with gestational diabetes, a new study suggests. , ... women being diagnosed with gestational diabetes, the new measurements ...
... ... ... ... ...
... ... ... , , , ... ...
... , ... ... ... ...
Cached Medicine News:Health News:New Treatment Eyed for Deadly Pancreatic Cancer 2Health News:New Treatment Eyed for Deadly Pancreatic Cancer 3Health News:Reading Remediation Seems to Rewire the Brain 2Health News:Reading Remediation Seems to Rewire the Brain 3Health News:Twice as Many Women May Soon Be Diagnosed With Gestational Diabetes 2Health News:Pelosi, Obama Mislead on Abortion Funding in Health Care Bill 2Health News:Pelosi, Obama Mislead on Abortion Funding in Health Care Bill 3Health News:Pelosi, Obama Mislead on Abortion Funding in Health Care Bill 4Health News:Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to 'Outsmart' Disease 2Health News:Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to 'Outsmart' Disease 3Health News:Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to 'Outsmart' Disease 4Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 2Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 3Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 4Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 5Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 6Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 7Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 8
... Osteopal V is a low viscosity bone ... in vertebroplasty. The bone cement is injected ... purposes. Osteopal V is used for the ... of zirconium dioxide is included in the ...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
... a comprehensive platform for standard neurosurgical ... to plan the optimal surgical path ... Combined with unique features such as ... planning tool, Neurosight becomes a very ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with our displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless...
Medicine Products: